Press releases 2009

Date		Headline
15/12/09		Oxford BioMedicas Stargen for Stargardt Disease Receives European Orphan Drug Designation
19/11/09		Oxford BioMedica Plc Interim Management Statement
15/10/09		Oxford BioMedica Announces Update on ProSavin® Phase I/II Trial in Parkinsons Disease And Publication of Preclinical Results
22/09/09		Oxford BioMedica Presents Interim Results From Phase III TRIST Study of TroVax® In Renal Cancer
04/09/09		Oxford BioMedica to Present at Rodman & Renshaw Global Investment Conference
01/09/09		Oxford BioMedica Plc (the Company) Directors Interest in Shares
27/08/09		Oxford BioMedica Plc Unaudited Interim Results for the Six Months Ended 30 June 2009
19/08/09		Oxford BioMedica Announces Acceptance of Late-Breaking Abstract on TroVax^® Phase III TRIST Study for Presentation at ECCO 15-34th ESMO Congress
07/08/09		Oxford Biomedica to Present at Canaccord Adams Global Growth Conference
05/08/09		Oxford BioMedica Notice of 2009 Interim Results
13/07/09		Oxford Biomedica Announces Update On Phase I/II Study Of ProSavin^® In Parkinson's Disease
06/07/09		Oxford Biomedica Announces Outcome of FDA Review And Updates On Trovax^® Phase III TRIST Study In Renal Cancer
18/06/09		Oxford BioMedica to present at Piper Jaffray Europe Conference
04/06/09		Oxford BioMedica Annual General Meeting
01/06/09		Oxford BioMedica Presents Updated TroVax^® Phase I/II and II Results at ASCO Annual Meeting
14/05/09		Oxford BioMedica Plc Interim Management Statement
11/05/09		Oxford BioMedica Continues to Reject Bavarian Nordic's Unwarranted Patent Infringement Claims
29/04/09		Oxford Biomedica Regains Rights to its Trovax^® Cancer Vaccine
29/04/09		Oxford Biomedica And Sanofi-Aventis Enter New Collaboration to Develop Gene-Based Treatments for Ocular Diseases
12/03/09		Oxford BioMedica Plc: Preliminary Results for the Year Ended 31 December 2008
25/02/09		Oxford BioMedica: Notice of FY2008 Preliminary Results
05/02/09		Oxford BioMedica Receives Further Investment Under Agreement Led by the Foundation Fighting Blindness
27/01/09		Oxford BioMedica Response to Bavarian Nordic's Re-filed US Litigation
12/01/09		Oxford BioMedica Announces Dismissal of Bavarian Nordic's Patent Infringement Claims